KemPharm (NASDAQ:KMPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Other analysts also recently issued research reports about the stock. Oppenheimer set a $13.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research report on Sunday, February 25th. Royal Bank of Canada set a $9.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research report on Tuesday, January 16th. Canaccord Genuity set a $11.00 price objective on shares of KemPharm and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, ValuEngine raised shares of KemPharm from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $9.70.
A hedge fund recently raised its stake in KemPharm stock. Victory Capital Management Inc. grew its holdings in shares of KemPharm Inc (NASDAQ:KMPH) by 26.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 162,077 shares of the specialty pharmaceutical company’s stock after buying an additional 34,114 shares during the quarter. Victory Capital Management Inc. owned 1.11% of KemPharm worth $656,000 as of its most recent SEC filing. Institutional investors own 36.56% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “KemPharm (KMPH) Downgraded by Zacks Investment Research to Hold” was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296544/kempharm-kmph-downgraded-by-zacks-investment-research-to-hold.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.